Share your contact details to receive free updated sample copy/pages of the recently published edition of Adult Vaccines Market Report 2023.
Key Insights from Adult Vaccines Market Report
As per Cognitive Market Research's latest published report, the Global Adult Vaccines market size was USD 16,792.21 million in 2022. Adult Vaccines Industry's Compound Annual Growth Rate will be 7.3% from 2023 to 2030.
Global Adult Vaccines Market Compound Annual Growth Rate (CAGR) for 2023 to 2030 | 7.3% |
Adult Vaccines Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Adult Vaccines Market Report Description
What is Adult Vaccine?
The vaccine is a biological constituent that endorses the formation of antibodies against several infections previously present in the body. It is naturally created using pathogens and chemical medications that help as antigens to defend against sickness. Conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and recombinant vaccines are the common types of vaccines in the market. They help in the prevention of several serious diseases, such as hepatitis, polio, diphtheria, meningitis, measles, influenza, tetanus, and rotavirus.
Factors Impacting on Adult Vaccines Market
Governments of many countries have issued mandatory instructions to use adult vaccines. This is attributed to increasing incidences of infectious diseases among adults that drive the global adult vaccine market growth. In addition, rising demand for better healthcare and a growing awareness level about the benefits of immunization dominate the global adult vaccine market. Furthermore, technological development in vaccine administration provides an opportunity for the global market.
However, high capital investment and a lack of technical professionals are the factors that hamper the growth of the global market. In addition, adverse effects associated with the vaccine muscle aches, fever, and many others that may hamper the market growth
Base Year | 2022 |
Historical Data Time Period | 2018-2022 |
Forecast Period | 2023-2030 |
Report Edition | 7th Edition (2023) |
Last Update | Last Updated In April 2023 |
Next Report Edition | June 2023 (Pre-Booking Available) |
Market Forecast/Projection Time Period | 2023-2030 |
Report Format | PDF | PPT | Excel | Word | Bi |
Report ID | CMR397103 |
Adult Vaccines Market Report 2023 (Global Edition) Table of Content differs according to the user License selection. Current Displayed TOC is for the Single User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report. Specific section/s of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)
- 1.1 Global Adult Vaccines Industry Introduction
- 1.2 Objectives of the Study
- 1.3 USP of the Report
- 1.4 Who is this report for?
- 1.5 Designing of Market Scope
- 1.5.1 Adult Vaccines Market Segmentation
- 1.5.1 Adult Vaccines Market Regional Fragmentation
- 1.5.1 Adult Vaccines Market Players
- 1.6 Report Duration
- 1.7 List of Stakeholders
- 2.1 Adult Vaccines Market Report 2023 Research Methodology
- 2.2 Systematic Research Approach
- 2.2.1 Primary Research
- 2.2.1.1 Key Data from Primary
- 2.2.1.2 Primary Interviews with Experts
- 2.2.1.3 Key Industry Insights
- 2.2.1.4 Questionnaire
At Cognitive Market Research, we have designed questionnaire focused on Adult Vaccines Market for the statistical study. This questionnaire is the key part of our research methodology which is shared with number of Adult Vaccines industry experts of entire value chain, located across the globe. This study help us to gather accurate quantitative and qualitative data for the final report.
- 2.2.1.5 Breakdown of Primaries
- 2.2.2 Secondary Research
- 2.2.2.1 Key Data from Secondary
- 2.2.2.2 Paid Sources
- 2.2.2.3 Public Sources
- 2.2.1 Primary Research
- 2.3 Market Size Estimation
- 2.3.1 Top-Down Approach
- 2.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 2.3.1 Bottom-UP Approach
- 2.3.1.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 2.3.1 Top-Down Approach
- 2.4 Market Breakdown and Data Triangulation
- 2.5 Research Assumptions
- 3.1 Global Adult Vaccines Market Size 2018 – 2030, (USD Million)
- 3.2 Global Adult Vaccines Value, Absolute & Opportunity Analysis
- 3.3 Global Adult Vaccines Market Y-o-Y Growth Rate Projection by Region (2023 - 2030)
- 3.4 Global Adult Vaccines Market Statistics 2022: Snapshot
- 4.1 Adult Vaccines Introduction
- 4.2 Global Adult Vaccines Market Statistics by Regions (2018-2030)
- 4.2.1 North America Adult Vaccines Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.2 Europe Adult Vaccines Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.3 Asia Pacific Adult Vaccines Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.4 Latin America Adult Vaccines Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.2.5 Middle East and Africa Adult Vaccines Market Share, Status and Prospect (2018 - 2030) and Value, Absolute & Opportunity Analysis
- 4.3 Global Adult Vaccines Market Size (2018-2030)
- 4.3.1 Global Adult Vaccines Revenue Status and Outlook (2018-2030)
- 4.4 Global Adult Vaccines Market Price Analysis by Regions (2018-2030)
- 5.1 Global Adult Vaccines Market Revenue and Share by Manufacturers (2018-2022)
- 5.2 Global Adult Vaccines Industry Mergers and Acquisition Analysis
- 5.3 Global Adult Vaccines New Launches Analysis
- 5.4 Company Categorization
- 5.5 Global Adult Vaccines Top Winning Strategies, by Manufacturers (2018-2022)
- 7.1 Adult Vaccines Industrial Dynamics
- 7.1.1 Global Adult Vaccines Market Drivers
- 7.1.2 Global Adult Vaccines Market Restrains
- 7.1.3 Global Adult Vaccines Market Opportunities
- 7.1.4 Global Adult Vaccines Market Trends
- 7.2 Adult Vaccines Market Attractiveness Analysis
- 7.1.1 Market Attractiveness Analysis by Type Segment
- 7.1.2 Market Attractiveness Analysis by Application Segment
- 7.3 PESTEL Analysis for Adult Vaccines Market
- 7.3.1 Political Factors
- 7.3.2 Economic Factors
- 7.3.3 Social Factors
- 7.3.4 Technological Factors
- 7.3.5 Legal Factors
- 7.3.6 Environmental Factors
- 7.4 Porter’s Five Forces Analysis for Adult Vaccines Market
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of Substitutes
- 7.4.4 Threat of New Entrants
- 7.4.5 Degree of Competition
- 7.5 COVID-19 Impact on Adult Vaccines Industry
- 7.4.1 Overall Impact of COVID-19 on Adult Vaccines Industry
- 7.4.2 Post COVID-19 Impact and Recovery Analysis
- 7.4.3 Influencing Factors
- 7.6 Consumer Preference Analysis for Adult Vaccines Market
- 7.7 Patent Analysis of Adult Vaccines
- 7.8 Adult Vaccines Industrial Chain Analysis
- 7.9 Manufacturing Cost Analysis
- 8.1 GlaxoSmithKline
- 8.1.1 GlaxoSmithKline Company Basic Information, and Sales Area
- 8.1.2 GlaxoSmithKline Business Segment/ Overview
- 8.1.3 GlaxoSmithKline Financials
- 8.1.3.1 Investment in Research and Development
- 8.1.3.2 GlaxoSmithKline Sales Revenue (2018-2022)
- 8.1.3.3 GlaxoSmithKline Market Share (2018-2022)
- 8.1.4 GlaxoSmithKline Recent Developments
- 8.1.5 GlaxoSmithKline Business Strategy
- 8.1.6 GlaxoSmithKline Management Change
- 8.1.7 GlaxoSmithKline
SWOT Analysis
- 8.1.7.1 Strength
- 8.1.7.2 Weakness
- 8.1.7.3 Opportunity
- 8.1.7.4 Threats
- 8.1.8 GlaxoSmithKline COVID-19 Impact Analysis
- 8.2 Sanofi Pasteur
- 8.2.1 Sanofi Pasteur Company Basic Information, and Sales Area
- 8.2.2 Sanofi Pasteur Business Segment/ Overview
- 8.2.3 Sanofi Pasteur Financials
- 8.2.3.1 Investment in Research and Development
- 8.2.3.2 Sanofi Pasteur Sales Revenue (2018-2022)
- 8.2.3.3 Sanofi Pasteur Market Share (2018-2022)
- 8.2.4 Sanofi Pasteur Recent Developments
- 8.2.5 Sanofi Pasteur Business Strategy
- 8.2.6 Sanofi Pasteur Management Change
- 8.2.7 Sanofi Pasteur
SWOT Analysis
- 8.2.7.1 Strength
- 8.2.7.2 Weakness
- 8.2.7.3 Opportunity
- 8.2.7.4 Threats
- 8.2.8 Sanofi Pasteur COVID-19 Impact Analysis
- 8.3 Merck
- 8.3.1 Merck Company Basic Information, and Sales Area
- 8.3.2 Merck Business Segment/ Overview
- 8.3.3 Merck Financials
- 8.3.3.1 Investment in Research and Development
- 8.3.3.2 Merck Sales Revenue (2018-2022)
- 8.3.3.3 Merck Market Share (2018-2022)
- 8.3.4 Merck Recent Developments
- 8.3.5 Merck Business Strategy
- 8.3.6 Merck Management Change
- 8.3.7 Merck
SWOT Analysis
- 8.3.7.1 Strength
- 8.3.7.2 Weakness
- 8.3.7.3 Opportunity
- 8.3.7.4 Threats
- 8.3.8 Merck COVID-19 Impact Analysis
- 8.4 Novartis
- 8.4.1 Novartis Company Basic Information, and Sales Area
- 8.4.2 Novartis Business Segment/ Overview
- 8.4.3 Novartis Financials
- 8.4.3.1 Investment in Research and Development
- 8.4.3.2 Novartis Sales Revenue (2018-2022)
- 8.4.3.3 Novartis Market Share (2018-2022)
- 8.4.4 Novartis Recent Developments
- 8.4.5 Novartis Business Strategy
- 8.4.6 Novartis Management Change
- 8.4.7 Novartis
SWOT Analysis
- 8.4.7.1 Strength
- 8.4.7.2 Weakness
- 8.4.7.3 Opportunity
- 8.4.7.4 Threats
- 8.4.8 Novartis COVID-19 Impact Analysis
- 8.5 Pfizer
- 8.5.1 Pfizer Company Basic Information, and Sales Area
- 8.5.2 Pfizer Business Segment/ Overview
- 8.5.3 Pfizer Financials
- 8.5.3.1 Investment in Research and Development
- 8.5.3.2 Pfizer Sales Revenue (2018-2022)
- 8.5.3.3 Pfizer Market Share (2018-2022)
- 8.5.4 Pfizer Recent Developments
- 8.5.5 Pfizer Business Strategy
- 8.5.6 Pfizer Management Change
- 8.5.7 Pfizer
SWOT Analysis
- 8.5.7.1 Strength
- 8.5.7.2 Weakness
- 8.5.7.3 Opportunity
- 8.5.7.4 Threats
- 8.5.8 Pfizer COVID-19 Impact Analysis
- 8.6 BioCSL (Seqirus)
- 8.6.1 BioCSL (Seqirus) Company Basic Information, and Sales Area
- 8.6.2 BioCSL (Seqirus) Business Segment/ Overview
- 8.6.3 BioCSL (Seqirus) Financials
- 8.6.3.1 Investment in Research and Development
- 8.6.3.2 BioCSL (Seqirus) Sales Revenue (2018-2022)
- 8.6.3.3 BioCSL (Seqirus) Market Share (2018-2022)
- 8.6.4 BioCSL (Seqirus) Recent Developments
- 8.6.5 BioCSL (Seqirus) Business Strategy
- 8.6.6 BioCSL (Seqirus) Management Change
- 8.6.7 BioCSL (Seqirus)
SWOT Analysis
- 8.6.7.1 Strength
- 8.6.7.2 Weakness
- 8.6.7.3 Opportunity
- 8.6.7.4 Threats
- 8.6.8 BioCSL (Seqirus) COVID-19 Impact Analysis
- 8.7 Protein Sciences
- 8.7.1 Protein Sciences Company Basic Information, and Sales Area
- 8.7.2 Protein Sciences Business Segment/ Overview
- 8.7.3 Protein Sciences Financials
- 8.7.3.1 Investment in Research and Development
- 8.7.3.2 Protein Sciences Sales Revenue (2018-2022)
- 8.7.3.3 Protein Sciences Market Share (2018-2022)
- 8.7.4 Protein Sciences Recent Developments
- 8.7.5 Protein Sciences Business Strategy
- 8.7.6 Protein Sciences Management Change
- 8.7.7 Protein Sciences SWOT Analysis
- 8.7.7.1 Strength
- 8.7.7.2 Weakness
- 8.7.7.3 Opportunity
- 8.7.7.4 Threats
- 8.7.8 Protein Sciences COVID-19 Impact Analysis
- 9.1 Detailed Qualitative Analysis
- 9.2 Global Adult Vaccines Revenue and Share (%) by Vaccine (2018-2030)
- 9.2.1 Hepatitis
Market Size
- 9.2.1.1 Global Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 9.2.1.2 Adult Vaccines Market for Hepatitis , by Country (2021 Vs 2024)
- 9.2.2 Human Papillomavirus
Market Size
- 9.2.2.1 Global Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 9.2.2.2 Adult Vaccines Market for Human Papillomavirus , by Country (2021 Vs 2024)
- 9.2.3 Influenza
Market Size
- 9.2.3.1 Global Influenza Market Share and Revenue (USD Million) for 2018-2030
- 9.2.3.2 Adult Vaccines Market for Influenza , by Country (2021 Vs 2024)
- 9.2.4 Zoster
Market Size
- 9.2.4.1 Global Zoster Market Share and Revenue (USD Million) for 2018-2030
- 9.2.4.2 Adult Vaccines Market for Zoster , by Country (2021 Vs 2024)
- 9.2.5 Others Market Size
- 9.2.5.1 Global Others Market Share and Revenue (USD Million) for 2018-2030
- 9.2.5.2 Adult Vaccines Market for Others, by Country (2021 Vs 2024)
- 9.2.1 Hepatitis
Market Size
- 10.1 Detailed Qualitative Analysis
- 10.2 Global Adult Vaccines Revenue and Share (%) by Technology (2018-2030)
- 10.2.1 Live Attenuated Vaccines
Market Size
- 10.2.1.1 Global Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 10.2.1.2 Adult Vaccines Market for Live Attenuated Vaccines , by Country (2021 Vs 2024)
- 10.2.2 Inactivated Viral/Bacterial Vaccines
Market Size
- 10.2.2.1 Global Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 10.2.2.2 Adult Vaccines Market for Inactivated Viral/Bacterial Vaccines , by Country (2021 Vs 2024)
- 10.2.3 Toxoid Vaccines
Market Size
- 10.2.3.1 Global Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 10.2.3.2 Adult Vaccines Market for Toxoid Vaccines , by Country (2021 Vs 2024)
- 10.2.4 Recombinant Vaccines
Market Size
- 10.2.4.1 Global Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 10.2.4.2 Adult Vaccines Market for Recombinant Vaccines , by Country (2021 Vs 2024)
- 10.2.5 Conjugate Vaccines Market Size
- 10.2.5.1 Global Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 10.2.5.2 Adult Vaccines Market for Conjugate Vaccines, by Country (2021 Vs 2024)
- 10.2.1 Live Attenuated Vaccines
Market Size
- 11.1 Detailed Qualitative Analysis
- 11.2 Global Adult Vaccines Revenue and Share (%) by Vaccine Type (2018-2030)
- 11.2.1 Monovalent
Market Size
- 11.2.1.1 Global Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 11.2.1.2 Adult Vaccines Market for Monovalent , by Country (2021 Vs 2024)
- 11.2.2 Multivalent Market Size
- 11.2.2.1 Global Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 11.2.2.2 Adult Vaccines Market for Multivalent, by Country (2021 Vs 2024)
- 11.2.1 Monovalent
Market Size
- 12.1 Detailed Qualitative Analysis
- 12.2 Global Adult Vaccines Market Revenue by Region (2018-2030)
- 12.3 Global Adult Vaccines Market Share (%) by Region (2018-2030)
- 13.1 North America
- 13.1.1 North America Adult Vaccines Market Trends and Analysis
- 13.1.2 North America Adult Vaccines Market by Country, 2018-2030
- 13.1.3 North America Adult Vaccines Market Attractiveness Analysis by Country
- 13.2 North America Adult Vaccines Market Size (2018-2030)
- 13.2.1 North America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.2.1.1 Hepatitis
- 13.2.1.1.1 North America Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.2 Human Papillomavirus
- 13.2.1.2.1 North America Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.3 Influenza
- 13.2.1.3.1 North America Influenza Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.4 Zoster
- 13.2.1.4.1 North America Zoster Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.5 Others
- 13.2.1.5.1 North America Others Market Share and Revenue (USD Million) for 2018-2030
- 13.2.1.1 Hepatitis
- 13.2.2 North America Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 13.2.2.1 Live Attenuated Vaccines
- 13.2.2.1.1 North America Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.2 Inactivated Viral/Bacterial Vaccines
- 13.2.2.2.1 North America Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.3 Toxoid Vaccines
- 13.2.2.3.1 North America Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.4 Recombinant Vaccines
- 13.2.2.4.1 North America Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.5 Conjugate Vaccines
- 13.2.2.5.1 North America Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.2.2.1 Live Attenuated Vaccines
- 13.2.3 North America Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 13.2.3.1 Monovalent
- 13.2.3.1.1 North America Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.2 Multivalent
- 13.2.3.2.1 North America Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 13.2.3.1 Monovalent
- 13.2.1 North America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.3 United States Adult Vaccines Market Size (2018-2030)
- 13.3.1 United States Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.3.1.1 Hepatitis
- 13.3.1.1.1 United States Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.2 Human Papillomavirus
- 13.3.1.2.1 United States Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.3 Influenza
- 13.3.1.3.1 United States Influenza Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.4 Zoster
- 13.3.1.4.1 United States Zoster Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.5 Others
- 13.3.1.5.1 United States Others Market Share and Revenue (USD Million) for 2018-2030
- 13.3.1.1 Hepatitis
- 13.3.2 United States Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 13.3.2.1 Live Attenuated Vaccines
- 13.3.2.1.1 United States Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.2 Inactivated Viral/Bacterial Vaccines
- 13.3.2.2.1 United States Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.3 Toxoid Vaccines
- 13.3.2.3.1 United States Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.4 Recombinant Vaccines
- 13.3.2.4.1 United States Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.5 Conjugate Vaccines
- 13.3.2.5.1 United States Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.3.2.1 Live Attenuated Vaccines
- 13.3.3 United States Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 13.3.3.1 Monovalent
- 13.3.3.1.1 United States Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 13.3.3.2 Multivalent
- 13.3.3.2.1 United States Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 13.3.3.1 Monovalent
- 13.3.1 United States Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.4 Canada Adult Vaccines Market Size (2018-2030)
- 13.4.1 Canada Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.4.1.1 Hepatitis
- 13.4.1.1.1 Canada Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.2 Human Papillomavirus
- 13.4.1.2.1 Canada Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.3 Influenza
- 13.4.1.3.1 Canada Influenza Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.4 Zoster
- 13.4.1.4.1 Canada Zoster Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.5 Others
- 13.4.1.5.1 Canada Others Market Share and Revenue (USD Million) for 2018-2030
- 13.4.1.1 Hepatitis
- 13.4.2 Canada Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 13.4.2.1 Live Attenuated Vaccines
- 13.4.2.1.1 Canada Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.2 Inactivated Viral/Bacterial Vaccines
- 13.4.2.2.1 Canada Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.3 Toxoid Vaccines
- 13.4.2.3.1 Canada Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.4 Recombinant Vaccines
- 13.4.2.4.1 Canada Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.5 Conjugate Vaccines
- 13.4.2.5.1 Canada Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.4.2.1 Live Attenuated Vaccines
- 13.4.3 Canada Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 13.4.3.1 Monovalent
- 13.4.3.1.1 Canada Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 13.4.3.2 Multivalent
- 13.4.3.2.1 Canada Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 13.4.3.1 Monovalent
- 13.4.1 Canada Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.5 Mexico Adult Vaccines Market Size (2018-2030)
- 13.5.1 Mexico Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 13.5.1.1 Hepatitis
- 13.5.1.1.1 Mexico Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.2 Human Papillomavirus
- 13.5.1.2.1 Mexico Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.3 Influenza
- 13.5.1.3.1 Mexico Influenza Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.4 Zoster
- 13.5.1.4.1 Mexico Zoster Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.5 Others
- 13.5.1.5.1 Mexico Others Market Share and Revenue (USD Million) for 2018-2030
- 13.5.1.1 Hepatitis
- 13.5.2 Mexico Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 13.5.2.1 Live Attenuated Vaccines
- 13.5.2.1.1 Mexico Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.2 Inactivated Viral/Bacterial Vaccines
- 13.5.2.2.1 Mexico Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.3 Toxoid Vaccines
- 13.5.2.3.1 Mexico Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.4 Recombinant Vaccines
- 13.5.2.4.1 Mexico Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.5 Conjugate Vaccines
- 13.5.2.5.1 Mexico Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 13.5.2.1 Live Attenuated Vaccines
- 13.5.3 Mexico Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 13.5.3.1 Monovalent
- 13.5.3.1.1 Mexico Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 13.5.3.2 Multivalent
- 13.5.3.2.1 Mexico Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 13.5.3.1 Monovalent
- 13.5.1 Mexico Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.1 Europe
- 14.1.1 Europe Adult Vaccines Market Trends and Analysis
- 14.1.2 Europe Adult Vaccines Market by Country, 2018-2030
- 14.1.3 Europe Adult Vaccines Market Attractiveness Analysis by Country
- 14.2 Europe Adult Vaccines Market Size (2018-2030)
- 14.2.1 Europe Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.2.1.1 Hepatitis
- 14.2.1.1.1 Europe Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.2 Human Papillomavirus
- 14.2.1.2.1 Europe Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.3 Influenza
- 14.2.1.3.1 Europe Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.4 Zoster
- 14.2.1.4.1 Europe Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.5 Others
- 14.2.1.5.1 Europe Others Market Share and Revenue (USD Million) for 2018-2030
- 14.2.1.1 Hepatitis
- 14.2.2 Europe Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.2.2.1 Live Attenuated Vaccines
- 14.2.2.1.1 Europe Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.2 Inactivated Viral/Bacterial Vaccines
- 14.2.2.2.1 Europe Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.3 Toxoid Vaccines
- 14.2.2.3.1 Europe Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.4 Recombinant Vaccines
- 14.2.2.4.1 Europe Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.5 Conjugate Vaccines
- 14.2.2.5.1 Europe Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.2.2.1 Live Attenuated Vaccines
- 14.2.3 Europe Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.2.3.1 Monovalent
- 14.2.3.1.1 Europe Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.2 Multivalent
- 14.2.3.2.1 Europe Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.2.3.1 Monovalent
- 14.2.1 Europe Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.3 United Kingdom Adult Vaccines Market Size (2018-2030)
- 14.3.1 United Kingdom Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.3.1.1 Hepatitis
- 14.3.1.1.1 United Kingdom Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.2 Human Papillomavirus
- 14.3.1.2.1 United Kingdom Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.3 Influenza
- 14.3.1.3.1 United Kingdom Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.4 Zoster
- 14.3.1.4.1 United Kingdom Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.5 Others
- 14.3.1.5.1 United Kingdom Others Market Share and Revenue (USD Million) for 2018-2030
- 14.3.1.1 Hepatitis
- 14.3.2 United Kingdom Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.3.2.1 Live Attenuated Vaccines
- 14.3.2.1.1 United Kingdom Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.2 Inactivated Viral/Bacterial Vaccines
- 14.3.2.2.1 United Kingdom Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.3 Toxoid Vaccines
- 14.3.2.3.1 United Kingdom Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.4 Recombinant Vaccines
- 14.3.2.4.1 United Kingdom Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.5 Conjugate Vaccines
- 14.3.2.5.1 United Kingdom Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.3.2.1 Live Attenuated Vaccines
- 14.3.3 United Kingdom Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.3.3.1 Monovalent
- 14.3.3.1.1 United Kingdom Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.3.3.2 Multivalent
- 14.3.3.2.1 United Kingdom Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.3.3.1 Monovalent
- 14.3.1 United Kingdom Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.4 France Adult Vaccines Market Size (2018-2030)
- 14.4.1 France Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.4.1.1 Hepatitis
- 14.4.1.1.1 France Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.2 Human Papillomavirus
- 14.4.1.2.1 France Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.3 Influenza
- 14.4.1.3.1 France Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.4 Zoster
- 14.4.1.4.1 France Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.5 Others
- 14.4.1.5.1 France Others Market Share and Revenue (USD Million) for 2018-2030
- 14.4.1.1 Hepatitis
- 14.4.2 France Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.4.2.1 Live Attenuated Vaccines
- 14.4.2.1.1 France Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.2 Inactivated Viral/Bacterial Vaccines
- 14.4.2.2.1 France Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.3 Toxoid Vaccines
- 14.4.2.3.1 France Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.4 Recombinant Vaccines
- 14.4.2.4.1 France Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.5 Conjugate Vaccines
- 14.4.2.5.1 France Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.4.2.1 Live Attenuated Vaccines
- 14.4.3 France Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.4.3.1 Monovalent
- 14.4.3.1.1 France Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.4.3.2 Multivalent
- 14.4.3.2.1 France Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.4.3.1 Monovalent
- 14.4.1 France Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.5 Germany Adult Vaccines Market Size (2018-2030)
- 14.5.1 Germany Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.5.1.1 Hepatitis
- 14.5.1.1.1 Germany Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.2 Human Papillomavirus
- 14.5.1.2.1 Germany Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.3 Influenza
- 14.5.1.3.1 Germany Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.4 Zoster
- 14.5.1.4.1 Germany Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.5 Others
- 14.5.1.5.1 Germany Others Market Share and Revenue (USD Million) for 2018-2030
- 14.5.1.1 Hepatitis
- 14.5.2 Germany Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.5.2.1 Live Attenuated Vaccines
- 14.5.2.1.1 Germany Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.2 Inactivated Viral/Bacterial Vaccines
- 14.5.2.2.1 Germany Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.3 Toxoid Vaccines
- 14.5.2.3.1 Germany Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.4 Recombinant Vaccines
- 14.5.2.4.1 Germany Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.5 Conjugate Vaccines
- 14.5.2.5.1 Germany Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.5.2.1 Live Attenuated Vaccines
- 14.5.3 Germany Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.5.3.1 Monovalent
- 14.5.3.1.1 Germany Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.5.3.2 Multivalent
- 14.5.3.2.1 Germany Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.5.3.1 Monovalent
- 14.5.1 Germany Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.6 Italy Adult Vaccines Market Size (2018-2030)
- 14.6.1 Italy Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.6.1.1 Hepatitis
- 14.6.1.1.1 Italy Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.2 Human Papillomavirus
- 14.6.1.2.1 Italy Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.3 Influenza
- 14.6.1.3.1 Italy Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.4 Zoster
- 14.6.1.4.1 Italy Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.5 Others
- 14.6.1.5.1 Italy Others Market Share and Revenue (USD Million) for 2018-2030
- 14.6.1.1 Hepatitis
- 14.6.2 Italy Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.6.2.1 Live Attenuated Vaccines
- 14.6.2.1.1 Italy Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.2 Inactivated Viral/Bacterial Vaccines
- 14.6.2.2.1 Italy Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.3 Toxoid Vaccines
- 14.6.2.3.1 Italy Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.4 Recombinant Vaccines
- 14.6.2.4.1 Italy Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.5 Conjugate Vaccines
- 14.6.2.5.1 Italy Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.6.2.1 Live Attenuated Vaccines
- 14.6.3 Italy Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.6.3.1 Monovalent
- 14.6.3.1.1 Italy Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.6.3.2 Multivalent
- 14.6.3.2.1 Italy Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.6.3.1 Monovalent
- 14.6.1 Italy Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.7 Russia Adult Vaccines Market Size (2018-2030)
- 14.7.1 Russia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.7.1.1 Hepatitis
- 14.7.1.1.1 Russia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.2 Human Papillomavirus
- 14.7.1.2.1 Russia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.3 Influenza
- 14.7.1.3.1 Russia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.4 Zoster
- 14.7.1.4.1 Russia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.5 Others
- 14.7.1.5.1 Russia Others Market Share and Revenue (USD Million) for 2018-2030
- 14.7.1.1 Hepatitis
- 14.7.2 Russia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.7.2.1 Live Attenuated Vaccines
- 14.7.2.1.1 Russia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.2 Inactivated Viral/Bacterial Vaccines
- 14.7.2.2.1 Russia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.3 Toxoid Vaccines
- 14.7.2.3.1 Russia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.4 Recombinant Vaccines
- 14.7.2.4.1 Russia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.5 Conjugate Vaccines
- 14.7.2.5.1 Russia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.7.2.1 Live Attenuated Vaccines
- 14.7.3 Russia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.7.3.1 Monovalent
- 14.7.3.1.1 Russia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.7.3.2 Multivalent
- 14.7.3.2.1 Russia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.7.3.1 Monovalent
- 14.7.1 Russia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.8 Spain Adult Vaccines Market Size (2018-2030)
- 14.8.1 Spain Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.8.1.1 Hepatitis
- 14.8.1.1.1 Spain Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.2 Human Papillomavirus
- 14.8.1.2.1 Spain Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.3 Influenza
- 14.8.1.3.1 Spain Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.4 Zoster
- 14.8.1.4.1 Spain Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.5 Others
- 14.8.1.5.1 Spain Others Market Share and Revenue (USD Million) for 2018-2030
- 14.8.1.1 Hepatitis
- 14.8.2 Spain Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.8.2.1 Live Attenuated Vaccines
- 14.8.2.1.1 Spain Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.2 Inactivated Viral/Bacterial Vaccines
- 14.8.2.2.1 Spain Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.3 Toxoid Vaccines
- 14.8.2.3.1 Spain Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.4 Recombinant Vaccines
- 14.8.2.4.1 Spain Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.5 Conjugate Vaccines
- 14.8.2.5.1 Spain Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.8.2.1 Live Attenuated Vaccines
- 14.8.3 Spain Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.8.3.1 Monovalent
- 14.8.3.1.1 Spain Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.8.3.2 Multivalent
- 14.8.3.2.1 Spain Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.8.3.1 Monovalent
- 14.8.1 Spain Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.9 Sweden Adult Vaccines Market Size (2018-2030)
- 14.9.1 Sweden Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.9.1.1 Hepatitis
- 14.9.1.1.1 Sweden Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.2 Human Papillomavirus
- 14.9.1.2.1 Sweden Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.3 Influenza
- 14.9.1.3.1 Sweden Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.4 Zoster
- 14.9.1.4.1 Sweden Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.5 Others
- 14.9.1.5.1 Sweden Others Market Share and Revenue (USD Million) for 2018-2030
- 14.9.1.1 Hepatitis
- 14.9.2 Sweden Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.9.2.1 Live Attenuated Vaccines
- 14.9.2.1.1 Sweden Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.2 Inactivated Viral/Bacterial Vaccines
- 14.9.2.2.1 Sweden Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.3 Toxoid Vaccines
- 14.9.2.3.1 Sweden Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.4 Recombinant Vaccines
- 14.9.2.4.1 Sweden Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.5 Conjugate Vaccines
- 14.9.2.5.1 Sweden Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.9.2.1 Live Attenuated Vaccines
- 14.9.3 Sweden Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.9.3.1 Monovalent
- 14.9.3.1.1 Sweden Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.9.3.2 Multivalent
- 14.9.3.2.1 Sweden Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.9.3.1 Monovalent
- 14.9.1 Sweden Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.10 Denmark Adult Vaccines Market Size (2018-2030)
- 14.10.1 Denmark Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.10.1.1 Hepatitis
- 14.10.1.1.1 Denmark Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.2 Human Papillomavirus
- 14.10.1.2.1 Denmark Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.3 Influenza
- 14.10.1.3.1 Denmark Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.4 Zoster
- 14.10.1.4.1 Denmark Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.5 Others
- 14.10.1.5.1 Denmark Others Market Share and Revenue (USD Million) for 2018-2030
- 14.10.1.1 Hepatitis
- 14.10.2 Denmark Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.10.2.1 Live Attenuated Vaccines
- 14.10.2.1.1 Denmark Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.2 Inactivated Viral/Bacterial Vaccines
- 14.10.2.2.1 Denmark Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.3 Toxoid Vaccines
- 14.10.2.3.1 Denmark Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.4 Recombinant Vaccines
- 14.10.2.4.1 Denmark Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.5 Conjugate Vaccines
- 14.10.2.5.1 Denmark Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.10.2.1 Live Attenuated Vaccines
- 14.10.3 Denmark Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.10.3.1 Monovalent
- 14.10.3.1.1 Denmark Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.10.3.2 Multivalent
- 14.10.3.2.1 Denmark Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.10.3.1 Monovalent
- 14.10.1 Denmark Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.11 Netherlands Adult Vaccines Market Size (2018-2030)
- 14.11.1 Netherlands Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.11.1.1 Hepatitis
- 14.11.1.1.1 Netherlands Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.2 Human Papillomavirus
- 14.11.1.2.1 Netherlands Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.3 Influenza
- 14.11.1.3.1 Netherlands Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.4 Zoster
- 14.11.1.4.1 Netherlands Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.5 Others
- 14.11.1.5.1 Netherlands Others Market Share and Revenue (USD Million) for 2018-2030
- 14.11.1.1 Hepatitis
- 14.11.2 Netherlands Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.11.2.1 Live Attenuated Vaccines
- 14.11.2.1.1 Netherlands Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.2 Inactivated Viral/Bacterial Vaccines
- 14.11.2.2.1 Netherlands Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.3 Toxoid Vaccines
- 14.11.2.3.1 Netherlands Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.4 Recombinant Vaccines
- 14.11.2.4.1 Netherlands Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.5 Conjugate Vaccines
- 14.11.2.5.1 Netherlands Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.11.2.1 Live Attenuated Vaccines
- 14.11.3 Netherlands Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.11.3.1 Monovalent
- 14.11.3.1.1 Netherlands Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.11.3.2 Multivalent
- 14.11.3.2.1 Netherlands Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.11.3.1 Monovalent
- 14.11.1 Netherlands Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.12 Switzerland Adult Vaccines Market Size (2018-2030)
- 14.12.1 Switzerland Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.12.1.1 Hepatitis
- 14.12.1.1.1 Switzerland Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.2 Human Papillomavirus
- 14.12.1.2.1 Switzerland Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.3 Influenza
- 14.12.1.3.1 Switzerland Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.4 Zoster
- 14.12.1.4.1 Switzerland Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.5 Others
- 14.12.1.5.1 Switzerland Others Market Share and Revenue (USD Million) for 2018-2030
- 14.12.1.1 Hepatitis
- 14.12.2 Switzerland Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.12.2.1 Live Attenuated Vaccines
- 14.12.2.1.1 Switzerland Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.2 Inactivated Viral/Bacterial Vaccines
- 14.12.2.2.1 Switzerland Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.3 Toxoid Vaccines
- 14.12.2.3.1 Switzerland Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.4 Recombinant Vaccines
- 14.12.2.4.1 Switzerland Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.5 Conjugate Vaccines
- 14.12.2.5.1 Switzerland Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.12.2.1 Live Attenuated Vaccines
- 14.12.3 Switzerland Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.12.3.1 Monovalent
- 14.12.3.1.1 Switzerland Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.12.3.2 Multivalent
- 14.12.3.2.1 Switzerland Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.12.3.1 Monovalent
- 14.12.1 Switzerland Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.13 Belgium Adult Vaccines Market Size (2018-2030)
- 14.13.1 Belgium Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 14.13.1.1 Hepatitis
- 14.13.1.1.1 Belgium Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.2 Human Papillomavirus
- 14.13.1.2.1 Belgium Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.3 Influenza
- 14.13.1.3.1 Belgium Influenza Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.4 Zoster
- 14.13.1.4.1 Belgium Zoster Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.5 Others
- 14.13.1.5.1 Belgium Others Market Share and Revenue (USD Million) for 2018-2030
- 14.13.1.1 Hepatitis
- 14.13.2 Belgium Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 14.13.2.1 Live Attenuated Vaccines
- 14.13.2.1.1 Belgium Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.2 Inactivated Viral/Bacterial Vaccines
- 14.13.2.2.1 Belgium Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.3 Toxoid Vaccines
- 14.13.2.3.1 Belgium Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.4 Recombinant Vaccines
- 14.13.2.4.1 Belgium Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.5 Conjugate Vaccines
- 14.13.2.5.1 Belgium Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 14.13.2.1 Live Attenuated Vaccines
- 14.13.3 Belgium Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 14.13.3.1 Monovalent
- 14.13.3.1.1 Belgium Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 14.13.3.2 Multivalent
- 14.13.3.2.1 Belgium Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 14.13.3.1 Monovalent
- 14.13.1 Belgium Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.1 Asia Pacific
- 15.1.1 Asia Pacific Adult Vaccines Market Trends and Analysis
- 15.1.2 Asia Pacific Adult Vaccines Market by Country, 2018-2030
- 15.1.3 Asia Pacific Adult Vaccines Market Attractiveness Analysis by Country
- 15.2 Asia Pacific Adult Vaccines Market Size (2018-2030)
- 15.2.1 Asia Pacific Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.2.1.1 Hepatitis
- 15.2.1.1.1 Asia Pacific Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.2 Human Papillomavirus
- 15.2.1.2.1 Asia Pacific Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.3 Influenza
- 15.2.1.3.1 Asia Pacific Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.4 Zoster
- 15.2.1.4.1 Asia Pacific Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.5 Others
- 15.2.1.5.1 Asia Pacific Others Market Share and Revenue (USD Million) for 2018-2030
- 15.2.1.1 Hepatitis
- 15.2.2 Asia Pacific Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.2.2.1 Live Attenuated Vaccines
- 15.2.2.1.1 Asia Pacific Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.2 Inactivated Viral/Bacterial Vaccines
- 15.2.2.2.1 Asia Pacific Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.3 Toxoid Vaccines
- 15.2.2.3.1 Asia Pacific Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.4 Recombinant Vaccines
- 15.2.2.4.1 Asia Pacific Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.5 Conjugate Vaccines
- 15.2.2.5.1 Asia Pacific Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.2.2.1 Live Attenuated Vaccines
- 15.2.3 Asia Pacific Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.2.3.1 Monovalent
- 15.2.3.1.1 Asia Pacific Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.2 Multivalent
- 15.2.3.2.1 Asia Pacific Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.2.3.1 Monovalent
- 15.2.1 Asia Pacific Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.3 China Adult Vaccines Market Size (2018-2030)
- 15.3.1 China Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.3.1.1 Hepatitis
- 15.3.1.1.1 China Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.2 Human Papillomavirus
- 15.3.1.2.1 China Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.3 Influenza
- 15.3.1.3.1 China Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.4 Zoster
- 15.3.1.4.1 China Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.5 Others
- 15.3.1.5.1 China Others Market Share and Revenue (USD Million) for 2018-2030
- 15.3.1.1 Hepatitis
- 15.3.2 China Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.3.2.1 Live Attenuated Vaccines
- 15.3.2.1.1 China Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.2 Inactivated Viral/Bacterial Vaccines
- 15.3.2.2.1 China Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.3 Toxoid Vaccines
- 15.3.2.3.1 China Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.4 Recombinant Vaccines
- 15.3.2.4.1 China Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.5 Conjugate Vaccines
- 15.3.2.5.1 China Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.3.2.1 Live Attenuated Vaccines
- 15.3.3 China Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.3.3.1 Monovalent
- 15.3.3.1.1 China Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.3.3.2 Multivalent
- 15.3.3.2.1 China Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.3.3.1 Monovalent
- 15.3.1 China Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.4 Japan Adult Vaccines Market Size (2018-2030)
- 15.4.1 Japan Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.4.1.1 Hepatitis
- 15.4.1.1.1 Japan Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.2 Human Papillomavirus
- 15.4.1.2.1 Japan Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.3 Influenza
- 15.4.1.3.1 Japan Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.4 Zoster
- 15.4.1.4.1 Japan Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.5 Others
- 15.4.1.5.1 Japan Others Market Share and Revenue (USD Million) for 2018-2030
- 15.4.1.1 Hepatitis
- 15.4.2 Japan Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.4.2.1 Live Attenuated Vaccines
- 15.4.2.1.1 Japan Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.2 Inactivated Viral/Bacterial Vaccines
- 15.4.2.2.1 Japan Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.3 Toxoid Vaccines
- 15.4.2.3.1 Japan Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.4 Recombinant Vaccines
- 15.4.2.4.1 Japan Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.5 Conjugate Vaccines
- 15.4.2.5.1 Japan Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.4.2.1 Live Attenuated Vaccines
- 15.4.3 Japan Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.4.3.1 Monovalent
- 15.4.3.1.1 Japan Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.4.3.2 Multivalent
- 15.4.3.2.1 Japan Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.4.3.1 Monovalent
- 15.4.1 Japan Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.5 Korea Adult Vaccines Market Size (2018-2030)
- 15.5.1 Korea Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.5.1.1 Hepatitis
- 15.5.1.1.1 Korea Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.2 Human Papillomavirus
- 15.5.1.2.1 Korea Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.3 Influenza
- 15.5.1.3.1 Korea Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.4 Zoster
- 15.5.1.4.1 Korea Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.5 Others
- 15.5.1.5.1 Korea Others Market Share and Revenue (USD Million) for 2018-2030
- 15.5.1.1 Hepatitis
- 15.5.2 Korea Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.5.2.1 Live Attenuated Vaccines
- 15.5.2.1.1 Korea Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.2 Inactivated Viral/Bacterial Vaccines
- 15.5.2.2.1 Korea Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.3 Toxoid Vaccines
- 15.5.2.3.1 Korea Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.4 Recombinant Vaccines
- 15.5.2.4.1 Korea Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.5 Conjugate Vaccines
- 15.5.2.5.1 Korea Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.5.2.1 Live Attenuated Vaccines
- 15.5.3 Korea Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.5.3.1 Monovalent
- 15.5.3.1.1 Korea Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.5.3.2 Multivalent
- 15.5.3.2.1 Korea Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.5.3.1 Monovalent
- 15.5.1 Korea Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.6 India Adult Vaccines Market Size (2018-2030)
- 15.6.1 India Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.6.1.1 Hepatitis
- 15.6.1.1.1 India Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.2 Human Papillomavirus
- 15.6.1.2.1 India Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.3 Influenza
- 15.6.1.3.1 India Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.4 Zoster
- 15.6.1.4.1 India Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.5 Others
- 15.6.1.5.1 India Others Market Share and Revenue (USD Million) for 2018-2030
- 15.6.1.1 Hepatitis
- 15.6.2 India Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.6.2.1 Live Attenuated Vaccines
- 15.6.2.1.1 India Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.2 Inactivated Viral/Bacterial Vaccines
- 15.6.2.2.1 India Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.3 Toxoid Vaccines
- 15.6.2.3.1 India Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.4 Recombinant Vaccines
- 15.6.2.4.1 India Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.5 Conjugate Vaccines
- 15.6.2.5.1 India Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.6.2.1 Live Attenuated Vaccines
- 15.6.3 India Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.6.3.1 Monovalent
- 15.6.3.1.1 India Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.6.3.2 Multivalent
- 15.6.3.2.1 India Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.6.3.1 Monovalent
- 15.6.1 India Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.7 Australia Adult Vaccines Market Size (2018-2030)
- 15.7.1 Australia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.7.1.1 Hepatitis
- 15.7.1.1.1 Australia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.2 Human Papillomavirus
- 15.7.1.2.1 Australia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.3 Influenza
- 15.7.1.3.1 Australia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.4 Zoster
- 15.7.1.4.1 Australia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.5 Others
- 15.7.1.5.1 Australia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.7.1.1 Hepatitis
- 15.7.2 Australia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.7.2.1 Live Attenuated Vaccines
- 15.7.2.1.1 Australia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.2 Inactivated Viral/Bacterial Vaccines
- 15.7.2.2.1 Australia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.3 Toxoid Vaccines
- 15.7.2.3.1 Australia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.4 Recombinant Vaccines
- 15.7.2.4.1 Australia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.5 Conjugate Vaccines
- 15.7.2.5.1 Australia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.7.2.1 Live Attenuated Vaccines
- 15.7.3 Australia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.7.3.1 Monovalent
- 15.7.3.1.1 Australia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.7.3.2 Multivalent
- 15.7.3.2.1 Australia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.7.3.1 Monovalent
- 15.7.1 Australia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.8 Philippines Adult Vaccines Market Size (2018-2030)
- 15.8.1 Philippines Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.8.1.1 Hepatitis
- 15.8.1.1.1 Philippines Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.2 Human Papillomavirus
- 15.8.1.2.1 Philippines Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.3 Influenza
- 15.8.1.3.1 Philippines Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.4 Zoster
- 15.8.1.4.1 Philippines Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.5 Others
- 15.8.1.5.1 Philippines Others Market Share and Revenue (USD Million) for 2018-2030
- 15.8.1.1 Hepatitis
- 15.8.2 Philippines Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.8.2.1 Live Attenuated Vaccines
- 15.8.2.1.1 Philippines Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.2 Inactivated Viral/Bacterial Vaccines
- 15.8.2.2.1 Philippines Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.3 Toxoid Vaccines
- 15.8.2.3.1 Philippines Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.4 Recombinant Vaccines
- 15.8.2.4.1 Philippines Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.5 Conjugate Vaccines
- 15.8.2.5.1 Philippines Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.8.2.1 Live Attenuated Vaccines
- 15.8.3 Philippines Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.8.3.1 Monovalent
- 15.8.3.1.1 Philippines Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.8.3.2 Multivalent
- 15.8.3.2.1 Philippines Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.8.3.1 Monovalent
- 15.8.1 Philippines Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.9 Singapore Adult Vaccines Market Size (2018-2030)
- 15.9.1 Singapore Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.9.1.1 Hepatitis
- 15.9.1.1.1 Singapore Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.2 Human Papillomavirus
- 15.9.1.2.1 Singapore Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.3 Influenza
- 15.9.1.3.1 Singapore Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.4 Zoster
- 15.9.1.4.1 Singapore Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.5 Others
- 15.9.1.5.1 Singapore Others Market Share and Revenue (USD Million) for 2018-2030
- 15.9.1.1 Hepatitis
- 15.9.2 Singapore Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.9.2.1 Live Attenuated Vaccines
- 15.9.2.1.1 Singapore Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.2 Inactivated Viral/Bacterial Vaccines
- 15.9.2.2.1 Singapore Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.3 Toxoid Vaccines
- 15.9.2.3.1 Singapore Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.4 Recombinant Vaccines
- 15.9.2.4.1 Singapore Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.5 Conjugate Vaccines
- 15.9.2.5.1 Singapore Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.9.2.1 Live Attenuated Vaccines
- 15.9.3 Singapore Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.9.3.1 Monovalent
- 15.9.3.1.1 Singapore Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.9.3.2 Multivalent
- 15.9.3.2.1 Singapore Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.9.3.1 Monovalent
- 15.9.1 Singapore Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.10 Malaysia Adult Vaccines Market Size (2018-2030)
- 15.10.1 Malaysia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.10.1.1 Hepatitis
- 15.10.1.1.1 Malaysia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.2 Human Papillomavirus
- 15.10.1.2.1 Malaysia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.3 Influenza
- 15.10.1.3.1 Malaysia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.4 Zoster
- 15.10.1.4.1 Malaysia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.5 Others
- 15.10.1.5.1 Malaysia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.10.1.1 Hepatitis
- 15.10.2 Malaysia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.10.2.1 Live Attenuated Vaccines
- 15.10.2.1.1 Malaysia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.2 Inactivated Viral/Bacterial Vaccines
- 15.10.2.2.1 Malaysia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.3 Toxoid Vaccines
- 15.10.2.3.1 Malaysia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.4 Recombinant Vaccines
- 15.10.2.4.1 Malaysia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.5 Conjugate Vaccines
- 15.10.2.5.1 Malaysia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.10.2.1 Live Attenuated Vaccines
- 15.10.3 Malaysia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.10.3.1 Monovalent
- 15.10.3.1.1 Malaysia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.10.3.2 Multivalent
- 15.10.3.2.1 Malaysia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.10.3.1 Monovalent
- 15.10.1 Malaysia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.11 Thailand Adult Vaccines Market Size (2018-2030)
- 15.11.1 Thailand Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.11.1.1 Hepatitis
- 15.11.1.1.1 Thailand Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.2 Human Papillomavirus
- 15.11.1.2.1 Thailand Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.3 Influenza
- 15.11.1.3.1 Thailand Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.4 Zoster
- 15.11.1.4.1 Thailand Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.5 Others
- 15.11.1.5.1 Thailand Others Market Share and Revenue (USD Million) for 2018-2030
- 15.11.1.1 Hepatitis
- 15.11.2 Thailand Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.11.2.1 Live Attenuated Vaccines
- 15.11.2.1.1 Thailand Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.2 Inactivated Viral/Bacterial Vaccines
- 15.11.2.2.1 Thailand Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.3 Toxoid Vaccines
- 15.11.2.3.1 Thailand Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.4 Recombinant Vaccines
- 15.11.2.4.1 Thailand Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.5 Conjugate Vaccines
- 15.11.2.5.1 Thailand Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.11.2.1 Live Attenuated Vaccines
- 15.11.3 Thailand Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.11.3.1 Monovalent
- 15.11.3.1.1 Thailand Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.11.3.2 Multivalent
- 15.11.3.2.1 Thailand Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.11.3.1 Monovalent
- 15.11.1 Thailand Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.12 Indonesia Adult Vaccines Market Size (2018-2030)
- 15.12.1 Indonesia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.12.1.1 Hepatitis
- 15.12.1.1.1 Indonesia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.2 Human Papillomavirus
- 15.12.1.2.1 Indonesia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.3 Influenza
- 15.12.1.3.1 Indonesia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.4 Zoster
- 15.12.1.4.1 Indonesia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.5 Others
- 15.12.1.5.1 Indonesia Others Market Share and Revenue (USD Million) for 2018-2030
- 15.12.1.1 Hepatitis
- 15.12.2 Indonesia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.12.2.1 Live Attenuated Vaccines
- 15.12.2.1.1 Indonesia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.2 Inactivated Viral/Bacterial Vaccines
- 15.12.2.2.1 Indonesia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.3 Toxoid Vaccines
- 15.12.2.3.1 Indonesia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.4 Recombinant Vaccines
- 15.12.2.4.1 Indonesia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.5 Conjugate Vaccines
- 15.12.2.5.1 Indonesia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.12.2.1 Live Attenuated Vaccines
- 15.12.3 Indonesia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.12.3.1 Monovalent
- 15.12.3.1.1 Indonesia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.12.3.2 Multivalent
- 15.12.3.2.1 Indonesia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.12.3.1 Monovalent
- 15.12.1 Indonesia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.13 Rest of APAC Adult Vaccines Market Size (2018-2030)
- 15.13.1 Rest of APAC Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 15.13.1.1 Hepatitis
- 15.13.1.1.1 Rest of APAC Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.2 Human Papillomavirus
- 15.13.1.2.1 Rest of APAC Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.3 Influenza
- 15.13.1.3.1 Rest of APAC Influenza Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.4 Zoster
- 15.13.1.4.1 Rest of APAC Zoster Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.5 Others
- 15.13.1.5.1 Rest of APAC Others Market Share and Revenue (USD Million) for 2018-2030
- 15.13.1.1 Hepatitis
- 15.13.2 Rest of APAC Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 15.13.2.1 Live Attenuated Vaccines
- 15.13.2.1.1 Rest of APAC Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.2 Inactivated Viral/Bacterial Vaccines
- 15.13.2.2.1 Rest of APAC Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.3 Toxoid Vaccines
- 15.13.2.3.1 Rest of APAC Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.4 Recombinant Vaccines
- 15.13.2.4.1 Rest of APAC Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.5 Conjugate Vaccines
- 15.13.2.5.1 Rest of APAC Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 15.13.2.1 Live Attenuated Vaccines
- 15.13.3 Rest of APAC Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 15.13.3.1 Monovalent
- 15.13.3.1.1 Rest of APAC Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 15.13.3.2 Multivalent
- 15.13.3.2.1 Rest of APAC Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 15.13.3.1 Monovalent
- 15.13.1 Rest of APAC Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.1 Latin America
- 16.1.1 Latin America Adult Vaccines Market Trends and Analysis
- 16.1.2 Latin America Adult Vaccines Market by Country, 2018-2030
- 16.1.3 Latin America Adult Vaccines Market Attractiveness Analysis by Country
- 16.2 Latin America Adult Vaccines Market Size (2018-2030)
- 16.2.1 Latin America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.2.1.1 Hepatitis
- 16.2.1.1.1 Latin America Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.2 Human Papillomavirus
- 16.2.1.2.1 Latin America Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.3 Influenza
- 16.2.1.3.1 Latin America Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.4 Zoster
- 16.2.1.4.1 Latin America Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.5 Others
- 16.2.1.5.1 Latin America Others Market Share and Revenue (USD Million) for 2018-2030
- 16.2.1.1 Hepatitis
- 16.2.2 Latin America Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.2.2.1 Live Attenuated Vaccines
- 16.2.2.1.1 Latin America Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.2 Inactivated Viral/Bacterial Vaccines
- 16.2.2.2.1 Latin America Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.3 Toxoid Vaccines
- 16.2.2.3.1 Latin America Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.4 Recombinant Vaccines
- 16.2.2.4.1 Latin America Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.5 Conjugate Vaccines
- 16.2.2.5.1 Latin America Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.2.2.1 Live Attenuated Vaccines
- 16.2.3 Latin America Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.2.3.1 Monovalent
- 16.2.3.1.1 Latin America Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.2 Multivalent
- 16.2.3.2.1 Latin America Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.2.3.1 Monovalent
- 16.2.1 Latin America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.3 Brazil Adult Vaccines Market Size (2018-2030)
- 16.3.1 Brazil Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.3.1.1 Hepatitis
- 16.3.1.1.1 Brazil Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.2 Human Papillomavirus
- 16.3.1.2.1 Brazil Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.3 Influenza
- 16.3.1.3.1 Brazil Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.4 Zoster
- 16.3.1.4.1 Brazil Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.5 Others
- 16.3.1.5.1 Brazil Others Market Share and Revenue (USD Million) for 2018-2030
- 16.3.1.1 Hepatitis
- 16.3.2 Brazil Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.3.2.1 Live Attenuated Vaccines
- 16.3.2.1.1 Brazil Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.2 Inactivated Viral/Bacterial Vaccines
- 16.3.2.2.1 Brazil Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.3 Toxoid Vaccines
- 16.3.2.3.1 Brazil Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.4 Recombinant Vaccines
- 16.3.2.4.1 Brazil Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.5 Conjugate Vaccines
- 16.3.2.5.1 Brazil Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.3.2.1 Live Attenuated Vaccines
- 16.3.3 Brazil Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.3.3.1 Monovalent
- 16.3.3.1.1 Brazil Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.3.3.2 Multivalent
- 16.3.3.2.1 Brazil Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.3.3.1 Monovalent
- 16.3.1 Brazil Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.4 Argentina Adult Vaccines Market Size (2018-2030)
- 16.4.1 Argentina Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.4.1.1 Hepatitis
- 16.4.1.1.1 Argentina Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.2 Human Papillomavirus
- 16.4.1.2.1 Argentina Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.3 Influenza
- 16.4.1.3.1 Argentina Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.4 Zoster
- 16.4.1.4.1 Argentina Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.5 Others
- 16.4.1.5.1 Argentina Others Market Share and Revenue (USD Million) for 2018-2030
- 16.4.1.1 Hepatitis
- 16.4.2 Argentina Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.4.2.1 Live Attenuated Vaccines
- 16.4.2.1.1 Argentina Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.2 Inactivated Viral/Bacterial Vaccines
- 16.4.2.2.1 Argentina Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.3 Toxoid Vaccines
- 16.4.2.3.1 Argentina Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.4 Recombinant Vaccines
- 16.4.2.4.1 Argentina Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.5 Conjugate Vaccines
- 16.4.2.5.1 Argentina Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.4.2.1 Live Attenuated Vaccines
- 16.4.3 Argentina Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.4.3.1 Monovalent
- 16.4.3.1.1 Argentina Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.4.3.2 Multivalent
- 16.4.3.2.1 Argentina Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.4.3.1 Monovalent
- 16.4.1 Argentina Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.5 Colombia Adult Vaccines Market Size (2018-2030)
- 16.5.1 Colombia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.5.1.1 Hepatitis
- 16.5.1.1.1 Colombia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.2 Human Papillomavirus
- 16.5.1.2.1 Colombia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.3 Influenza
- 16.5.1.3.1 Colombia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.4 Zoster
- 16.5.1.4.1 Colombia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.5 Others
- 16.5.1.5.1 Colombia Others Market Share and Revenue (USD Million) for 2018-2030
- 16.5.1.1 Hepatitis
- 16.5.2 Colombia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.5.2.1 Live Attenuated Vaccines
- 16.5.2.1.1 Colombia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.2 Inactivated Viral/Bacterial Vaccines
- 16.5.2.2.1 Colombia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.3 Toxoid Vaccines
- 16.5.2.3.1 Colombia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.4 Recombinant Vaccines
- 16.5.2.4.1 Colombia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.5 Conjugate Vaccines
- 16.5.2.5.1 Colombia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.5.2.1 Live Attenuated Vaccines
- 16.5.3 Colombia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.5.3.1 Monovalent
- 16.5.3.1.1 Colombia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.5.3.2 Multivalent
- 16.5.3.2.1 Colombia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.5.3.1 Monovalent
- 16.5.1 Colombia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.6 Peru Adult Vaccines Market Size (2018-2030)
- 16.6.1 Peru Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.6.1.1 Hepatitis
- 16.6.1.1.1 Peru Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.2 Human Papillomavirus
- 16.6.1.2.1 Peru Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.3 Influenza
- 16.6.1.3.1 Peru Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.4 Zoster
- 16.6.1.4.1 Peru Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.5 Others
- 16.6.1.5.1 Peru Others Market Share and Revenue (USD Million) for 2018-2030
- 16.6.1.1 Hepatitis
- 16.6.2 Peru Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.6.2.1 Live Attenuated Vaccines
- 16.6.2.1.1 Peru Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.2 Inactivated Viral/Bacterial Vaccines
- 16.6.2.2.1 Peru Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.3 Toxoid Vaccines
- 16.6.2.3.1 Peru Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.4 Recombinant Vaccines
- 16.6.2.4.1 Peru Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.5 Conjugate Vaccines
- 16.6.2.5.1 Peru Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.6.2.1 Live Attenuated Vaccines
- 16.6.3 Peru Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.6.3.1 Monovalent
- 16.6.3.1.1 Peru Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.6.3.2 Multivalent
- 16.6.3.2.1 Peru Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.6.3.1 Monovalent
- 16.6.1 Peru Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.7 Chile Adult Vaccines Market Size (2018-2030)
- 16.7.1 Chile Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.7.1.1 Hepatitis
- 16.7.1.1.1 Chile Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.2 Human Papillomavirus
- 16.7.1.2.1 Chile Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.3 Influenza
- 16.7.1.3.1 Chile Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.4 Zoster
- 16.7.1.4.1 Chile Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.5 Others
- 16.7.1.5.1 Chile Others Market Share and Revenue (USD Million) for 2018-2030
- 16.7.1.1 Hepatitis
- 16.7.2 Chile Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.7.2.1 Live Attenuated Vaccines
- 16.7.2.1.1 Chile Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.2 Inactivated Viral/Bacterial Vaccines
- 16.7.2.2.1 Chile Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.3 Toxoid Vaccines
- 16.7.2.3.1 Chile Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.4 Recombinant Vaccines
- 16.7.2.4.1 Chile Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.5 Conjugate Vaccines
- 16.7.2.5.1 Chile Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.7.2.1 Live Attenuated Vaccines
- 16.7.3 Chile Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.7.3.1 Monovalent
- 16.7.3.1.1 Chile Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.7.3.2 Multivalent
- 16.7.3.2.1 Chile Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.7.3.1 Monovalent
- 16.7.1 Chile Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.8 Rest of South America Adult Vaccines Market Size (2018-2030)
- 16.8.1 Rest of South America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 16.8.1.1 Hepatitis
- 16.8.1.1.1 Rest of South America Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.2 Human Papillomavirus
- 16.8.1.2.1 Rest of South America Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.3 Influenza
- 16.8.1.3.1 Rest of South America Influenza Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.4 Zoster
- 16.8.1.4.1 Rest of South America Zoster Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.5 Others
- 16.8.1.5.1 Rest of South America Others Market Share and Revenue (USD Million) for 2018-2030
- 16.8.1.1 Hepatitis
- 16.8.2 Rest of South America Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 16.8.2.1 Live Attenuated Vaccines
- 16.8.2.1.1 Rest of South America Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.2 Inactivated Viral/Bacterial Vaccines
- 16.8.2.2.1 Rest of South America Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.3 Toxoid Vaccines
- 16.8.2.3.1 Rest of South America Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.4 Recombinant Vaccines
- 16.8.2.4.1 Rest of South America Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.5 Conjugate Vaccines
- 16.8.2.5.1 Rest of South America Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 16.8.2.1 Live Attenuated Vaccines
- 16.8.3 Rest of South America Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 16.8.3.1 Monovalent
- 16.8.3.1.1 Rest of South America Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 16.8.3.2 Multivalent
- 16.8.3.2.1 Rest of South America Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 16.8.3.1 Monovalent
- 16.8.1 Rest of South America Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.1 Middle East and Africa
- 17.1.1 Middle East and Africa Adult Vaccines Market Trends and Analysis
- 17.1.2 Middle East and Africa Adult Vaccines Market by Country, 2018-2030
- 17.1.3 Middle East and Africa Adult Vaccines Market Attractiveness Analysis by Country
- 17.2 Middle East and Africa Adult Vaccines Market Size (2018-2030)
- 17.2.1 Middle East and Africa Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.2.1.1 Hepatitis
- 17.2.1.1.1 Middle East and Africa Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.2 Human Papillomavirus
- 17.2.1.2.1 Middle East and Africa Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.3 Influenza
- 17.2.1.3.1 Middle East and Africa Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.4 Zoster
- 17.2.1.4.1 Middle East and Africa Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.5 Others
- 17.2.1.5.1 Middle East and Africa Others Market Share and Revenue (USD Million) for 2018-2030
- 17.2.1.1 Hepatitis
- 17.2.2 Middle East and Africa Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.2.2.1 Live Attenuated Vaccines
- 17.2.2.1.1 Middle East and Africa Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.2 Inactivated Viral/Bacterial Vaccines
- 17.2.2.2.1 Middle East and Africa Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.3 Toxoid Vaccines
- 17.2.2.3.1 Middle East and Africa Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.4 Recombinant Vaccines
- 17.2.2.4.1 Middle East and Africa Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.5 Conjugate Vaccines
- 17.2.2.5.1 Middle East and Africa Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.2.2.1 Live Attenuated Vaccines
- 17.2.3 Middle East and Africa Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.2.3.1 Monovalent
- 17.2.3.1.1 Middle East and Africa Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.2 Multivalent
- 17.2.3.2.1 Middle East and Africa Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.2.3.1 Monovalent
- 17.2.1 Middle East and Africa Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.3 Saudi Arabia Adult Vaccines Market Size (2018-2030)
- 17.3.1 Saudi Arabia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.3.1.1 Hepatitis
- 17.3.1.1.1 Saudi Arabia Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.2 Human Papillomavirus
- 17.3.1.2.1 Saudi Arabia Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.3 Influenza
- 17.3.1.3.1 Saudi Arabia Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.4 Zoster
- 17.3.1.4.1 Saudi Arabia Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.5 Others
- 17.3.1.5.1 Saudi Arabia Others Market Share and Revenue (USD Million) for 2018-2030
- 17.3.1.1 Hepatitis
- 17.3.2 Saudi Arabia Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.3.2.1 Live Attenuated Vaccines
- 17.3.2.1.1 Saudi Arabia Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.2 Inactivated Viral/Bacterial Vaccines
- 17.3.2.2.1 Saudi Arabia Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.3 Toxoid Vaccines
- 17.3.2.3.1 Saudi Arabia Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.4 Recombinant Vaccines
- 17.3.2.4.1 Saudi Arabia Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.5 Conjugate Vaccines
- 17.3.2.5.1 Saudi Arabia Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.3.2.1 Live Attenuated Vaccines
- 17.3.3 Saudi Arabia Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.3.3.1 Monovalent
- 17.3.3.1.1 Saudi Arabia Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.3.3.2 Multivalent
- 17.3.3.2.1 Saudi Arabia Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.3.3.1 Monovalent
- 17.3.1 Saudi Arabia Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.4 Turkey Adult Vaccines Market Size (2018-2030)
- 17.4.1 Turkey Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.4.1.1 Hepatitis
- 17.4.1.1.1 Turkey Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.2 Human Papillomavirus
- 17.4.1.2.1 Turkey Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.3 Influenza
- 17.4.1.3.1 Turkey Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.4 Zoster
- 17.4.1.4.1 Turkey Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.5 Others
- 17.4.1.5.1 Turkey Others Market Share and Revenue (USD Million) for 2018-2030
- 17.4.1.1 Hepatitis
- 17.4.2 Turkey Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.4.2.1 Live Attenuated Vaccines
- 17.4.2.1.1 Turkey Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.2 Inactivated Viral/Bacterial Vaccines
- 17.4.2.2.1 Turkey Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.3 Toxoid Vaccines
- 17.4.2.3.1 Turkey Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.4 Recombinant Vaccines
- 17.4.2.4.1 Turkey Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.5 Conjugate Vaccines
- 17.4.2.5.1 Turkey Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.4.2.1 Live Attenuated Vaccines
- 17.4.3 Turkey Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.4.3.1 Monovalent
- 17.4.3.1.1 Turkey Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.4.3.2 Multivalent
- 17.4.3.2.1 Turkey Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.4.3.1 Monovalent
- 17.4.1 Turkey Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.5 Nigeria Adult Vaccines Market Size (2018-2030)
- 17.5.1 Nigeria Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.5.1.1 Hepatitis
- 17.5.1.1.1 Nigeria Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.2 Human Papillomavirus
- 17.5.1.2.1 Nigeria Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.3 Influenza
- 17.5.1.3.1 Nigeria Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.4 Zoster
- 17.5.1.4.1 Nigeria Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.5 Others
- 17.5.1.5.1 Nigeria Others Market Share and Revenue (USD Million) for 2018-2030
- 17.5.1.1 Hepatitis
- 17.5.2 Nigeria Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.5.2.1 Live Attenuated Vaccines
- 17.5.2.1.1 Nigeria Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.2 Inactivated Viral/Bacterial Vaccines
- 17.5.2.2.1 Nigeria Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.3 Toxoid Vaccines
- 17.5.2.3.1 Nigeria Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.4 Recombinant Vaccines
- 17.5.2.4.1 Nigeria Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.5 Conjugate Vaccines
- 17.5.2.5.1 Nigeria Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.5.2.1 Live Attenuated Vaccines
- 17.5.3 Nigeria Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.5.3.1 Monovalent
- 17.5.3.1.1 Nigeria Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.5.3.2 Multivalent
- 17.5.3.2.1 Nigeria Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.5.3.1 Monovalent
- 17.5.1 Nigeria Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.6 UAE Adult Vaccines Market Size (2018-2030)
- 17.6.1 UAE Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.6.1.1 Hepatitis
- 17.6.1.1.1 UAE Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.2 Human Papillomavirus
- 17.6.1.2.1 UAE Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.3 Influenza
- 17.6.1.3.1 UAE Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.4 Zoster
- 17.6.1.4.1 UAE Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.5 Others
- 17.6.1.5.1 UAE Others Market Share and Revenue (USD Million) for 2018-2030
- 17.6.1.1 Hepatitis
- 17.6.2 UAE Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.6.2.1 Live Attenuated Vaccines
- 17.6.2.1.1 UAE Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.2 Inactivated Viral/Bacterial Vaccines
- 17.6.2.2.1 UAE Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.3 Toxoid Vaccines
- 17.6.2.3.1 UAE Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.4 Recombinant Vaccines
- 17.6.2.4.1 UAE Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.5 Conjugate Vaccines
- 17.6.2.5.1 UAE Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.6.2.1 Live Attenuated Vaccines
- 17.6.3 UAE Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.6.3.1 Monovalent
- 17.6.3.1.1 UAE Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.6.3.2 Multivalent
- 17.6.3.2.1 UAE Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.6.3.1 Monovalent
- 17.6.1 UAE Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.7 Egypt Adult Vaccines Market Size (2018-2030)
- 17.7.1 Egypt Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.7.1.1 Hepatitis
- 17.7.1.1.1 Egypt Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.2 Human Papillomavirus
- 17.7.1.2.1 Egypt Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.3 Influenza
- 17.7.1.3.1 Egypt Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.4 Zoster
- 17.7.1.4.1 Egypt Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.5 Others
- 17.7.1.5.1 Egypt Others Market Share and Revenue (USD Million) for 2018-2030
- 17.7.1.1 Hepatitis
- 17.7.2 Egypt Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.7.2.1 Live Attenuated Vaccines
- 17.7.2.1.1 Egypt Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.2 Inactivated Viral/Bacterial Vaccines
- 17.7.2.2.1 Egypt Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.3 Toxoid Vaccines
- 17.7.2.3.1 Egypt Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.4 Recombinant Vaccines
- 17.7.2.4.1 Egypt Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.5 Conjugate Vaccines
- 17.7.2.5.1 Egypt Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.7.2.1 Live Attenuated Vaccines
- 17.7.3 Egypt Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.7.3.1 Monovalent
- 17.7.3.1.1 Egypt Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.7.3.2 Multivalent
- 17.7.3.2.1 Egypt Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.7.3.1 Monovalent
- 17.7.1 Egypt Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.8 South Africa Adult Vaccines Market Size (2018-2030)
- 17.8.1 South Africa Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.8.1.1 Hepatitis
- 17.8.1.1.1 South Africa Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.2 Human Papillomavirus
- 17.8.1.2.1 South Africa Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.3 Influenza
- 17.8.1.3.1 South Africa Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.4 Zoster
- 17.8.1.4.1 South Africa Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.5 Others
- 17.8.1.5.1 South Africa Others Market Share and Revenue (USD Million) for 2018-2030
- 17.8.1.1 Hepatitis
- 17.8.2 South Africa Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.8.2.1 Live Attenuated Vaccines
- 17.8.2.1.1 South Africa Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.2 Inactivated Viral/Bacterial Vaccines
- 17.8.2.2.1 South Africa Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.3 Toxoid Vaccines
- 17.8.2.3.1 South Africa Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.4 Recombinant Vaccines
- 17.8.2.4.1 South Africa Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.5 Conjugate Vaccines
- 17.8.2.5.1 South Africa Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.8.2.1 Live Attenuated Vaccines
- 17.8.3 South Africa Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.8.3.1 Monovalent
- 17.8.3.1.1 South Africa Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.8.3.2 Multivalent
- 17.8.3.2.1 South Africa Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.8.3.1 Monovalent
- 17.8.1 South Africa Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.9 GCC Countries Adult Vaccines Market Size (2018-2030)
- 17.9.1 GCC Countries Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.9.1.1 Hepatitis
- 17.9.1.1.1 GCC Countries Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.2 Human Papillomavirus
- 17.9.1.2.1 GCC Countries Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.3 Influenza
- 17.9.1.3.1 GCC Countries Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.4 Zoster
- 17.9.1.4.1 GCC Countries Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.5 Others
- 17.9.1.5.1 GCC Countries Others Market Share and Revenue (USD Million) for 2018-2030
- 17.9.1.1 Hepatitis
- 17.9.2 GCC Countries Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.9.2.1 Live Attenuated Vaccines
- 17.9.2.1.1 GCC Countries Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.2 Inactivated Viral/Bacterial Vaccines
- 17.9.2.2.1 GCC Countries Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.3 Toxoid Vaccines
- 17.9.2.3.1 GCC Countries Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.4 Recombinant Vaccines
- 17.9.2.4.1 GCC Countries Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.5 Conjugate Vaccines
- 17.9.2.5.1 GCC Countries Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.9.2.1 Live Attenuated Vaccines
- 17.9.3 GCC Countries Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.9.3.1 Monovalent
- 17.9.3.1.1 GCC Countries Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.9.3.2 Multivalent
- 17.9.3.2.1 GCC Countries Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.9.3.1 Monovalent
- 17.9.1 GCC Countries Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.10 Rest of MEA Adult Vaccines Market Size (2018-2030)
- 17.10.1 Rest of MEA Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 17.10.1.1 Hepatitis
- 17.10.1.1.1 Rest of MEA Hepatitis Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.2 Human Papillomavirus
- 17.10.1.2.1 Rest of MEA Human Papillomavirus Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.3 Influenza
- 17.10.1.3.1 Rest of MEA Influenza Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.4 Zoster
- 17.10.1.4.1 Rest of MEA Zoster Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.5 Others
- 17.10.1.5.1 Rest of MEA Others Market Share and Revenue (USD Million) for 2018-2030
- 17.10.1.1 Hepatitis
- 17.10.2 Rest of MEA Adult Vaccines Market (USD Million) by Technology (2018-2030)
- 17.10.2.1 Live Attenuated Vaccines
- 17.10.2.1.1 Rest of MEA Live Attenuated Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.2 Inactivated Viral/Bacterial Vaccines
- 17.10.2.2.1 Rest of MEA Inactivated Viral/Bacterial Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.3 Toxoid Vaccines
- 17.10.2.3.1 Rest of MEA Toxoid Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.4 Recombinant Vaccines
- 17.10.2.4.1 Rest of MEA Recombinant Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.5 Conjugate Vaccines
- 17.10.2.5.1 Rest of MEA Conjugate Vaccines Market Share and Revenue (USD Million) for 2018-2030
- 17.10.2.1 Live Attenuated Vaccines
- 17.10.3 Rest of MEA Adult Vaccines Market (USD Million) by Vaccine Type (2018-2030)
- 17.10.3.1 Monovalent
- 17.10.3.1.1 Rest of MEA Monovalent Market Share and Revenue (USD Million) for 2018-2030
- 17.10.3.2 Multivalent
- 17.10.3.2.1 Rest of MEA Multivalent Market Share and Revenue (USD Million) for 2018-2030
- 17.10.3.1 Monovalent
- 17.10.1 Rest of MEA Adult Vaccines Market (USD Million) by Vaccine (2018-2030)
- 18.1 Key Takeaways
- 18.2 Analyst Point of View
Segmentation Level Customization | |
Global level Data Customization | |
Region level Data Customization | |
Country level Data Customization | |
Company Level | |
Additional Data Analysis | |
Additional Qualitative Data | |
Additional Quantitative Data | |
Service Level Customization | Report Format Alteration |
We have various report editions of Adult Vaccines Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Adult Vaccines Market Analysis
Global Adult Vaccines Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Adult Vaccines Industry growth. Adult Vaccines market has been segmented with the help of its Vaccine, Technology Vaccine Type, and others. Adult Vaccines market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Report scope is customizable as we have a huge database of Adult Vaccines industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Major Vaccine Analysed |
|
Major Technology Analysed |
|
Major Vaccine Type Analysed |
|
Top Manufacturers Disclosed | |
Global, Regional and Country Analysis |
|
Key Qualitative Information Covered |
|
By Vaccines, the Influenza segment has the major revenue share of Adult VaccineMarket!
Based on Vaccines, the market is segmented into human papillomavirus, influenza, zoster, hepatitis, and others. The Influenza segment has the major revenue share during the forecast period. Increasing cases of asthma, pneumonia, acute respiratory infection, and other diseases caused by influenza are forecasted to dominate the target market.
- Hepatitis
- Human Papillomavirus
- Influenza
- Zoster
- Others
Adult Vaccines Market Share (%) by Vaccine in 2018-2030
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Adult Vaccines Industry. Request a Free Sample PDF!
By Technology, the Recombinant segment is forecasted to dominate the Adult Vaccines Market!
By Technology, the market is segmented into inactivated viral/bacterial vaccines, live attenuated vaccines, toxoid vaccines, conjugate vaccines, and recombinant vaccines, The Recombinant segment is forecasted to dominate the global market, due to higher production, sales, and demand for recombinant.
- Live Attenuated Vaccines
- Inactivated Viral/Bacterial Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
Adult Vaccines Market Share (%) by Technology in 2018-2030
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Adult Vaccines market report 2023 Edition by contacting our team.
Adult Vaccines Vaccine Type Segment Analysis
By Vaccine-type, the market is segmented into multivalent vaccines and monovalent vaccines. The Multivalent vaccines segment has the highest revenue share due to increasing incidences of bacterial and viral diseases boosting the demand for the target market.
- Monovalent
- Multivalent
Regional Analysis of the Adult Vaccine Market:
North America and Europe dominate the global adult vaccine market with the highest revenue share. This is attributed to the increasing research and development infrastructure in this region fuels the growth of the market. Furthermore, Asia Pacific is forecasted to dominate the global market in terms of growth rate. Various government associations have introduced various programs to promote awareness among people towards diseases such as DYP, measles, and many others in the region in the countries.
Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Adult Vaccines Market Share (%) by Region (2018-2030)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Adult Vaccine Industry News:
GlaxoSmithKline plc announced US FDA approval of Priorix
June 2022, GlaxoSmithKline plc announced that they submitted a Biologics License Application (BLA) to the US FDA for its experimental vaccination PRIORIX. This vaccine is used for the prevention of mumps, rubella, and measles in individuals 12 months old and older over. Additionally, 100 nations have granted licenses for the vaccine, initially registered in Germany.
Top Companies Market Share in Adult Vaccines Industry: (In no particular order of Rank)
- GlaxoSmithKline
- Sanofi Pasteur
- Merck
- Novartis
- Pfizer
- BioCSL (Seqirus)
- Protein Sciences
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Adult Vaccines Market is witnessing significant growth in the near future.
In 2022, the Hepatitis segment accounted for noticeable share of global Adult Vaccines Market and is projected to experience significant growth in the near future.
The Live Attenuated Vaccines segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies GlaxoSmithKline , Merck and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Author's Detail
Surabhi Bhaiyya, LinkedIn
Senior Research Analyst at Cognitive Market Research
Surabhi Bhaiyya is an experienced market researcher focused on the Pharma & Healthcare industry. With over 7+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry. To get in touch and access the above report book an apointment at https://calendly.com/speak-to-analyst.
Key Questions Answered By Adult Vaccines Market Report 2023
Why Hepatitis have a significant impact on Adult Vaccines market? |
What are the key factors affecting the Hepatitis and Human Papillomavirus of Adult Vaccines Market? |
What is the CAGR/Growth Rate of Live Attenuated Vaccines during the forecast period? |
By type, which segment accounted for largest share of the global Adult Vaccines Market? |
Which region is expected to dominate the global Adult Vaccines Market within the forecast period? |
Frequently Asked Questions
Related Reports
- Measures to Explore Untapped Market
- Understanding Market Dynamics
- Understanding Changing Economics
- Competitors Market Share
- Global/Region/Country Level Analysis
- Identify Upcoming End Use Industries
- Global Price Trend Analysis
- Value Chain Analysis
- Customer Sentiment/Need Analysis
- Identification of Key Growth Segments
- Industry Upstream and Downstream Analysis
- Raw Material Sourcing and Cost Analysis
- Identify Key Customers Across Globe
- Concept Development and Market Testing
- Merger-Acquisition Strategy
- The research study and report are been made exclusively for an institution or person who is strategizing to build a business or strategically wants to expand certain portfolio.
- This report will help in analyzing complete market scenario across the globe who wish to expand their current business or is willing to invest in some profitable sector.
- This report will prove beneficial for person or an organization who wish to be updated regarding their business environment, consumers’ behaviour, and their requirements. The environment is constantly changing, and in such scenario, this report will help in understanding market parameters through 360-degree view.
- The report is thus ideal for KOL, CEO's, CFO's, directors, and others. It is also helpful to senior executives, business development managers, marketing managers, and consultants. Furthermore, government bodies, agencies and other kind of organizations can also leverage our report to understand market.
- Our objective for the Adult Vaccines market is to help in making imperative business decisions, securing investments, determining new business opportunities in the market. Further, the report helps to analyze overall marketing needs of customers, and avoid business failures.
- To know the potential market size and growth rate before launching a new product line. The report in a way helps in designing R&D budget wisely by estimating maximum total profit.
- To identify the Adult Vaccines market dynamics, industrial insights, and economic progression for critical information about the market conditions and specific business landscape.
- To assess the overall competitive landscape of a particular business sector and to provide complete analysis in regards with various external factors impacting the market growth.
- To create a strong foundation for building a strategy and foster insight into market conditions so that market players can make better business decisions. Besides, we aim to provide a complete portfolio of the major players involved the market.
- To define the scope which will further help in creating new products that will surpass the gap between current offerings and customers’ needs.
- To help in revealing significant clues concerning buying habits, regional culture, lifestyle, and population density that plays an integral role in shaping market behavior.
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market.
- Competitors Analysis: We provide data from the supplier side covering key details such as market share split among 1st tier, 2nd tier, and 3rd tier, Emerging Players, and Start-Ups. (whereas most of our competitors published data for top-tier companies)
- We provide market revenue share not only for Public listed companies but also the privately listed companies.
- Country Analysis: The Country level market split analysis is part of the report hence the data granularity is provided.
- We have been closely working with the Top 500 Fortune businesses, our clientele spanning 20+ industries. Our clientele is a mix of investors, manufacturers, end-users, distributors, etc. With our data subscription model (Athenaeum) 70% of clients have already subscribed/purchased reports for multiple years which helped us achieve unbelievable client retention statistics.
- Product + Service: In terms of the product we deliver the report access (PDF+ PPT+ EXCEL+ Cloud+ POWER BI) whereas in terms of service; we provide data support where a dedicated research analyst will be assigned and add-on benefits. (Whereas most of our competitors believe only in delivering the data/report and service and support remain questionable.)
- Credibility and Data Accuracy: We deliver accuracy close to 90-95% with the help of our in-house research team, freelancer, and industry expert network, sources present worldwide. This Data is backed up by strong What are our clients saying about our services.
Read more